These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 36523869)

  • 1. Editorial: The glutamate hypothesis of mood disorders: Neuroplasticity processes, clinical features, treatment perspectives.
    Guglielmo R; de Filippis R; Ouanes S; Hasler G
    Front Psychiatry; 2022; 13():1054887. PubMed ID: 36523869
    [No Abstract]   [Full Text] [Related]  

  • 2. The Mechanisms Behind Rapid Antidepressant Effects of Ketamine: A Systematic Review With a Focus on Molecular Neuroplasticity.
    Kang MJY; Hawken E; Vazquez GH
    Front Psychiatry; 2022; 13():860882. PubMed ID: 35546951
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The neuroprotective and neuroplastic potential of glutamatergic therapeutic drugs in bipolar disorder.
    Guglielmo R; Hasler G
    Neurosci Biobehav Rev; 2022 Nov; 142():104906. PubMed ID: 36206993
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Current Status of Ketamine and Related Therapies for Mood and Anxiety Disorders.
    Costi S; Van Dam NT; Murrough JW
    Curr Behav Neurosci Rep; 2015 Dec; 2(4):216-225. PubMed ID: 26783510
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Towards a glutamate hypothesis of depression: an emerging frontier of neuropsychopharmacology for mood disorders.
    Sanacora G; Treccani G; Popoli M
    Neuropharmacology; 2012 Jan; 62(1):63-77. PubMed ID: 21827775
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neuroplasticity and depression: Rewiring the brain's networks through pharmacological therapy (Review).
    Rădulescu I; Drăgoi AM; Trifu SC; Cristea MB
    Exp Ther Med; 2021 Oct; 22(4):1131. PubMed ID: 34504581
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neuroplasticity as a convergent mechanism of ketamine and classical psychedelics.
    Aleksandrova LR; Phillips AG
    Trends Pharmacol Sci; 2021 Nov; 42(11):929-942. PubMed ID: 34565579
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sleep Markers in Psychiatry: Do Insomnia and Disturbed Sleep Play as Markers of Disrupted Neuroplasticity in Mood Disorders? A Proposed Model.
    Palagini L; Geoffroy PA; Riemann D
    Curr Med Chem; 2022; 29(35):5595-5605. PubMed ID: 34906053
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The neurobiology of psychedelic drugs: implications for the treatment of mood disorders.
    Vollenweider FX; Kometer M
    Nat Rev Neurosci; 2010 Sep; 11(9):642-51. PubMed ID: 20717121
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ketamine-Induced Glutamatergic Mechanisms of Sleep and Wakefulness: Insights for Developing Novel Treatments for Disturbed Sleep and Mood.
    Duncan WC; Ballard ED; Zarate CA
    Handb Exp Pharmacol; 2019; 253():337-358. PubMed ID: 28939975
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of glutamate in mood disorders: results from the ketamine in major depression study and the presumed cellular mechanism underlying its antidepressant effects.
    Maeng S; Zarate CA
    Curr Psychiatry Rep; 2007 Dec; 9(6):467-74. PubMed ID: 18221626
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serotonin and neuroplasticity - Links between molecular, functional and structural pathophysiology in depression.
    Kraus C; Castrén E; Kasper S; Lanzenberger R
    Neurosci Biobehav Rev; 2017 Jun; 77():317-326. PubMed ID: 28342763
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel Glutamatergic Modulators for the Treatment of Mood Disorders: Current Status.
    Henter ID; Park LT; Zarate CA
    CNS Drugs; 2021 May; 35(5):527-543. PubMed ID: 33904154
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Leveraging Neuroplasticity to Enhance Adaptive Learning: The Potential for Synergistic Somatic-Behavioral Treatment Combinations to Improve Clinical Outcomes in Depression.
    Wilkinson ST; Holtzheimer PE; Gao S; Kirwin DS; Price RB
    Biol Psychiatry; 2019 Mar; 85(6):454-465. PubMed ID: 30528745
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Metabotropic glutamate receptors in the control of mood disorders.
    Witkin JM; Marek GJ; Johnson BG; Schoepp DD
    CNS Neurol Disord Drug Targets; 2007 Apr; 6(2):87-100. PubMed ID: 17430147
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting glutamatergic signaling for the development of novel therapeutics for mood disorders.
    Machado-Vieira R; Salvadore G; Ibrahim LA; Diaz-Granados N; Zarate CA
    Curr Pharm Des; 2009; 15(14):1595-611. PubMed ID: 19442176
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Glutamate: The Master Neurotransmitter and Its Implications in Chronic Stress and Mood Disorders.
    Pal MM
    Front Hum Neurosci; 2021; 15():722323. PubMed ID: 34776901
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Acute ketamine-induced neuroplasticity: ribosomal protein S6 phosphorylation expression in drug addiction-related rat brain areas.
    Tedesco V; Ravagnani C; Bertoglio D; Chiamulera C
    Neuroreport; 2013 May; 24(7):388-93. PubMed ID: 23568219
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Glutamate modulators as novel interventions for mood disorders.
    Mathew SJ; Keegan K; Smith L
    Braz J Psychiatry; 2005 Sep; 27(3):243-8. PubMed ID: 16224615
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genetic Studies on the Tripartite Glutamate Synapse in the Pathophysiology and Therapeutics of Mood Disorders.
    de Sousa RT; Loch AA; Carvalho AF; Brunoni AR; Haddad MR; Henter ID; Zarate CA; Machado-Vieira R
    Neuropsychopharmacology; 2017 Mar; 42(4):787-800. PubMed ID: 27510426
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.